{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:11:29Z","timestamp":1793949089752,"version":"4.8.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014461","name":"NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust\/Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000764","name":"King's College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1053\/j.semnuclmed.2022.01.005","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T06:50:18Z","timestamp":1645944618000},"page":"531-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Imaging of Bone Metastases in Breast Cancer"],"prefix":"10.1053","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8732-8134","authenticated-orcid":false,"given":"Gary J.R.","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0001","first-page":"103","article-title":"Factors associated with mortality after breast cancer metastasis","volume":"23","author":"Jung","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0002","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-6-179","article-title":"Clinical management of women with metastatic breast cancer: A descriptive study according to age group","volume":"6","author":"Manders","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0003","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer: Implications for management","volume":"36","author":"Plunkett","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.anndiagpath.2010.06.010","article-title":"Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs","volume":"15","author":"Wei","year":"2011","journal-title":"Ann Diagn Pathol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0005","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO;2-3","article-title":"Predictors of skeletal complications in patients with metastatic breast carcinoma","volume":"89","author":"Domchek","year":"2000","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0006","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: Mechanisms, therapies, and biomarkers","volume":"101","author":"Cl\u00e9zardin","year":"2021","journal-title":"Physiol Rev"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0007","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0008","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2967\/jnumed.119.234260","article-title":"Molecular imaging of bone metastases and their response to therapy","volume":"61","author":"Cook","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0009","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/jbmr.3444","article-title":"Functional and hybrid imaging of bone metastases","volume":"33","author":"Cook","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1053\/j.semnuclmed.2022.01.005_bib0010","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.2967\/jnumed.115.157867","article-title":"Imaging bone metastases in breast cancer: Staging and response assessment","volume":"57","author":"Cook","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0011","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growth in cancer of the breast","volume":"1","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0012","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrc3793","article-title":"Mechanisms of disseminated cancer cell dormancy: An awakening field","volume":"14","author":"Sosa","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2022.01.005_bib0013","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"15","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/snuc.2001.18742","article-title":"Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate","volume":"31","author":"Blake","year":"2001","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0015","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.semnuclmed.2009.07.003","article-title":"Patterns, variants, artifacts, and pitfalls in conventional radionuclide bone imaging and SPECT\/CT","volume":"39","author":"Gnanasegaran","year":"2009","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0016","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1200\/JCO.1995.13.5.1123","article-title":"Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer","volume":"13","author":"Vogel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0017","first-page":"1354","article-title":"Bone scan flare predicts successful systemic therapy for bone metastases","volume":"29","author":"Coleman","year":"1988","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0018","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00259-018-4223-9","article-title":"Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET\/CT with whole-body MRI with diffusion-weighted imaging","volume":"46","author":"Azad","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0019","first-page":"311","article-title":"Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide","volume":"48","author":"Sprague","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0020","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2967\/jnumed.109.067140","article-title":"Targeting the alphavbeta3 integrin for small-animal PET\/CT of osteolytic bone metastases","volume":"50","author":"Wadas","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0021","doi-asserted-by":"crossref","first-page":"75587","DOI":"10.18632\/oncotarget.17486","article-title":"Clinical study of (99m)Tc-3P-RGD2 peptide imaging in osteolytic bone metastasis","volume":"8","author":"Shao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0022","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00259-017-3926-7","article-title":"Imaging \u03b1v\u03b23 integrin expression in skeletal metastases with 99mTc-maraciclatide Single-Photon Emission Computed Tomography: detection and therapy response assessment","volume":"45","author":"Cook","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0023","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1196\/annals.1346.017","article-title":"Osteoclasts and integrins","volume":"1068","author":"Teitelbaum","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0024","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s00259-015-3080-z","article-title":"Appearance of untreated bone metastases from breast cancer on FDG PET\/CT: Importance of histologic subtype","volume":"42","author":"Dashevsky","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0025","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.1998.16.10.3375","article-title":"Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions","volume":"16","author":"Cook","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0026","doi-asserted-by":"crossref","first-page":"e1277","DOI":"10.1634\/theoncologist.2019-0096","article-title":"18F-FES PET\/CT influences the staging and management of patients with newly diagnosed estrogen receptor-positive breast cancer: A retrospective comparative study with 18F-FDG PET\/CT","volume":"24","author":"Liu","year":"2019","journal-title":"Oncologist"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0027","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1634\/theoncologist.2019-0967","article-title":"Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16\u03b1-18F-Fluoro-17\u03b2-estradiol positron emission tomography: Meta-analysis and recommendations for integration into clinical applications","volume":"25","author":"Kurland","year":"2020","journal-title":"Oncologist"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0028","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients","volume":"48","author":"Giesel","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0029","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00259-021-05442-9","article-title":"68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer","volume":"49","author":"Ding","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1754-9485.2009.02070.x","article-title":"Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer","volume":"53","author":"Venkitaraman","year":"2009","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0031","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s00330-013-2792-3","article-title":"MRI for response assessment in metastatic bone disease","volume":"23","author":"Lecouvet","year":"2013","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0032","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/jmri.24548","article-title":"Therapy monitoring of skeletal metastases with whole-body diffusion MRI","volume":"39","author":"Padhani","year":"2014","journal-title":"J Magn Reson Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0033","first-page":"744","article-title":"Technetium-99m-methylene diphosphonate\u2013a superior agent for skeletal imaging: Comparison with other technetium complexes","volume":"16","author":"Subramanian","year":"1975","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0034","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1148\/radiol.2373041358","article-title":"Added value of SPECT\/CT fusion in assessing suspected bone metastasis: Comparison with scintigraphy alone and nonfused scintigraphy and CT","volume":"238","author":"Utsunomiya","year":"2001","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0035","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s00259-009-1334-3","article-title":"The added value of multislice SPECT\/CT in patients with equivocal bony metastasis from carcinoma of the prostate","volume":"37","author":"Helyar","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0036","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/1097-0142(19830815)52:4<610::AID-CNCR2820520406>3.0.CO;2-5","article-title":"Assessment of response of bone metastases to systemic treatment in patients with breast cancer","volume":"52","author":"Coombes","year":"1983","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0037","doi-asserted-by":"crossref","first-page":"228e47","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0038","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.bjc.6605546","article-title":"Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer","volume":"102","author":"Hamaoka","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0039","first-page":"332","article-title":"Fluorine-18: A new isotope for bone scanning","volume":"3","author":"Blau","year":"1962","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0040","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/MNM.0000000000000568","article-title":"Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer","volume":"37","author":"Abikhzer","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0041","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.2967\/jnumed.115.162610","article-title":"Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET\/CT, and whole-body MRI in patients with breast and prostate cancer","volume":"56","author":"Minamimoto","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0042","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11604-013-0179-7","article-title":"The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: A comparison with FDG PET\/CT and 99mTc-MDP bone scan","volume":"31","author":"Damle","year":"2013","journal-title":"Jpn J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0043","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.2967\/jnumed.113.135475","article-title":"Impact of (18)F-Fluoride PET on intended management of patients with cancers other than prostate cancer: Results from the National Oncologic PET Registry","volume":"55","author":"Hillner","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0044","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00259-018-4223-9","article-title":"Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET\/CT with whole-body MRI with diffusion-weighted imaging","volume":"46","author":"Azad","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0045","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.109.070052","article-title":"Kinetic analysis of 18F-fluoride PET images of breast cancer bone metastases","volume":"51","author":"Doot","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0046","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2967\/jnumed.118.208710","article-title":"Is response assessment of breast cancer bone metastases better with measurement of 18F-Fluoride metabolic flux than with measurement of 18F-Fluoride PET\/CT SUV?","volume":"60","author":"Azad","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0047","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.114.150391","article-title":"18F-fluoride PET used for treatment monitoring of systemic cancer therapy: Results from the National Oncologic PET Registry","volume":"56","author":"Hillner","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0048","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00259-005-1842-8","article-title":"Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer","volume":"32","author":"Nakai","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0049","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00259-006-0141-3","article-title":"FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy","volume":"33","author":"Israel","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/RLU.0b013e31815f23b7","article-title":"Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer","volume":"33","author":"Shie","year":"2008","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0051","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.suronc.2013.01.002","article-title":"Comparison of 18FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis","volume":"22","author":"Rong","year":"2013","journal-title":"Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0052","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00256-010-0963-8","article-title":"A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer","volume":"40","author":"Liu","year":"2011","journal-title":"Skeletal Radiol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0053","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiol.2471070567","article-title":"Bone metastases in patients with metastatic breast cancer: Morphologic and metabolic monitoring of response to systemic therapy with integrated PET\/CT","volume":"247","author":"Tateishi","year":"2008","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0054","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1076-6332(03)80461-0","article-title":"Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy","author":"Stafford","year":"2002","journal-title":"Acad Radiol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-006-9435-1","article-title":"Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)","volume":"105","author":"Specht","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0056","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2967\/jnumed.110.076455","article-title":"18F-FDG PET\/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer","volume":"51","author":"De Giorgi","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0057","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0058","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00259-011-1981-z","article-title":"Assessment of response to endocrine therapy using FDG PET\/CT in metastatic breast cancer: A pilot study","volume":"39","author":"Mortazavi-Jehanno","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0059","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2967\/jnumed.118.211102","article-title":"Prospective study of serial 18F-FDG PET and 18F-Fluoride PET to predict time to skeletal-related events, time to progression, and survival in patients with bone-dominant metastatic breast cancer","volume":"59","author":"Peterson","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2021.109821","article-title":"Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET\/CT and [18F]Fluorodeoxyglucose PET\/CT","volume":"141","author":"Bottoni","year":"2021","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0061","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.2967\/jnumed.117.198846","article-title":"18F-Fluoroestradiol tumor uptake is heterogeneous and influenced by site of metastasis in breast cancer patients","volume":"59","author":"Nienhuis","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0062","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clbc.2013.02.012","article-title":"Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?","volume":"13","author":"Yang","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0063","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1007\/s12149-021-01616-5","article-title":"68Ga-FAPI-04 PET\/CT, a new step in breast cancer imaging: A comparative pilot study with the 18F-FDG PET\/CT","volume":"35","author":"K\u00f6mek","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0064","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s12149-021-01672-x","article-title":"Superiority of 68Ga-FAPI PET\/CT scan in detecting additional lesions compared to 18FDG PET\/CT scan in breast cancer","volume":"35","author":"Elboga","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/jmri.22608","article-title":"Diagnostic value of whole-body magnetic resonance imaging for bone metastases: A systematic review and meta-analysis","volume":"34","author":"Wu","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0066","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/0284186X.2015.1027411","article-title":"Prospective evaluation of planar bone scintigraphy, SPECT, SPECT\/CT, 18F-NaF PET\/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial","volume":"55","author":"Jambor","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0067","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00259-010-1399-z","article-title":"Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET\/CT for whole-body breast cancer staging","volume":"37","author":"Heusner","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.01.005_bib0068","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2967\/jnumed.113.123646","article-title":"Performance of whole-body integrated 18F-FDG PET\/MR in comparison to PET\/CT for evaluation of malignant bone lesions","volume":"55","author":"Eiber","year":"2014","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:59:38Z","timestamp":1762073978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822000058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0001299822000058"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.01.005","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging of Bone Metastases in Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}